{"disease":{"id":"b-precursor-acute-lymphoblastic-leukemia","name":"b precursor acute lymphoblastic leukemia"},"drugs":{"marketed":[{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06763302","title":"NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1220,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT03123887","title":"Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL","phase":"","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Harbin Hematology and Oncology Institute","has_results":false},{"nct_id":"NCT07223190","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":560,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02013167","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":405,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04994717","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":304,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04521231","title":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":281,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02303522","title":"Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)","phase":"","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02315612","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02614066","title":"A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT02412306","title":"Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04629729","title":"FT819 in Subjects With B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT01925131","title":"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT06054113","title":"Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04506086","title":"Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06649006","title":"Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03982992","title":"Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false},{"nct_id":"NCT02187354","title":"Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Amgen","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}